Immediate and Midterm Complications of Sclerotherapy: Report of a Prospective Multicenter Registry of 12,173 Sclerotherapy Sessions

Guex, J. J.; Allaert, François-André; Gillet, J.-L.; Chleir, F.

doi:10.1111/j.1524-4725.2005.31030

Cited by 187 publications

(245 citation statements)

References 10 publications

Supporting

Mentioning

207

Contrasting

Unclassified

Order By: Relevance

“…Most studies report an incidence of transient neurologic events after EFS of less than 1% without long-term sequelae. 7,[12][13][14][15][16]22 Currently, the presence of PFO is not considered a contraindication to EFS, although a restricted amount of foam is recommended in patients with symptomatic PFO. 23 Screening for PFO in patients undergoing EFS is considered unnecessary.…”

Section: Adverse Eventsmentioning

confidence: 99%

Effectiveness of foam sclerotherapy for the treatment of varicose veins

Nael

Rathbun

2009

Vasc Med

View full text Add to dashboard Cite

Varicose veins (VVs) are associated with lifestyle-limiting symptoms and complications. Patients who fail compression therapy are candidates for more invasive treatments. This study evaluates the efficacy and safety of endovenous foam sclerotherapy (EFS) for the treatment of VVs in a US academic center. We reviewed medical records of a consecutive cohort of patients who underwent EFS over a 2-year period. The primary outcome measure was obliteration of VVs. The secondary outcome measures were symptomatic improvement, ulcer healing, recurrence, and adverse events. A total of 166 patients (217 legs) underwent EFS for pain (81%), pruritis (41%), swelling (17%), ulcerations (17%), thrombophlebitis (14%), and varix rupture (3%). Complete (65%) or near-complete (34%) obliteration was achieved in 215 (99%) legs after one injection. Additional injections achieved complete obliteration in 39 of 53 legs. Ninety-three percent (27/29) of active ulcers healed or were decreasing in size. Five ulcers and 11 VVs recurred. Common adverse events included pain and hyperpigmentation. Thrombosis, hematoma, skin necrosis, and neurologic events were rare. In conclusion, EFS appears to be a safe and effective outpatient therapy for the treatment of symptomatic and complicated VVs.

show abstract

Section: Adverse Eventsmentioning

confidence: 99%

Effectiveness of foam sclerotherapy for the treatment of varicose veins

Nael

Rathbun

2009

Vasc Med

View full text Add to dashboard Cite

show abstract

“…The required pressures are only reached concentrically at the thigh with bandages, however, and not with MCS (3,11,19). Following foam sclerotherapy, superficial varicose veins very clearly benefit from compression (1,8,13,15,20).…”

Section: Discussionmentioning

confidence: 99%

Film compression bandage

Ragg¹

2015

Phlebologie

View full text Add to dashboard Cite

KeywordsFilm bandage, compression, sports, varicose vein, foam sclerotherapy SummaryPurpose: Textile compression stockings or bandages are limited in comfort; they do not allow uninterrupted wearing. A novel elastic film bandage was evaluated regarding practicability, patient comfort and effect on vein regression. Main endpoint was the frequency of symptomatic inflammatory reactions. Methods: In a comparative pilot study, a compression film bandage (CFB, investigational) comprising an elastic, self-adhesive breathable polymer film of d <20 µm was continuously worn for 14 d after foam sclerotherapy. Inclusion: 62 patients (26-68 y.) frequently doing sports and taking daily showers, 90 legs with superficial varicosities, 5-12 mm ø (MW: 7.3 mm), randomized to A) CFB + medical compression stocking (MCS), B) MCS alone, C) CFB alone. Follow-up examinations including ultrasound and photography were performed after 2, 4 and 8 weeks.Results: Continuous wearing time of 14 days was completed in 57/60 cases with CFB (95.0 %, A+C), while 3/60 (5.0 %) finished wearing after 8-10 d. There were no adverse skin reactions except minor irritations at the upper edge (n = 2). Vein diameters were reduced within 14 days by 29-54 % (mean: 43.5 %) in group A, 16-44% (mean: 39.1 %) in group B, and 24-50 % (mean: 37.3 %) in group C. Symptomatic inflammation, induration or discolouration was observed within 28 days in 5/60 cases (8.3 %) when using CFB (A, C) versus 19/30 (63.3%) related to stocking compression (B). Comfort was rated by the patients 6.6 (A), 4.3 (B) and 9.2 (C) on a 10 degree scale. This difference was statistically highly significant (p <0.01). Conclusions: The film bandage is an effective and safe compression modality. For superficial varicosities the adhesive bond to the skin seems to be relevant additional to the elastic properties. The device significantly improves vein regression of foam-treated superficial varicosities when combined with compression stockings or even as stand-alone modality. Continuous wearing for two weeks is well tolerated. The bandage may also offer an alternative for patients not tolerating textile compression media, or during summer.

show abstract

“…However, not all serotype 2 strains are virulent, and degree of virulence varies among strains (2). Previous studies have reported several S. suis putative virulence factors, including the polysaccharide capsule, the muramidase-released protein, the extracellular factor, and suilysin (3)(4)(5). Some of these factors have been used as virulence-associated markers, and the association of the factors of S. suis isolates with virulence or clinical background has been suggested in Europe (2,5).…”

Section: Streptococcus Suis In Humans Thailandmentioning

confidence: 99%